[go: up one dir, main page]

CL2018003352A1 - Compuestos de carfilzomib pegilados. - Google Patents

Compuestos de carfilzomib pegilados.

Info

Publication number
CL2018003352A1
CL2018003352A1 CL2018003352A CL2018003352A CL2018003352A1 CL 2018003352 A1 CL2018003352 A1 CL 2018003352A1 CL 2018003352 A CL2018003352 A CL 2018003352A CL 2018003352 A CL2018003352 A CL 2018003352A CL 2018003352 A1 CL2018003352 A1 CL 2018003352A1
Authority
CL
Chile
Prior art keywords
compounds
carfilzomib compounds
pegylated carfilzomib
pegylated
treat
Prior art date
Application number
CL2018003352A
Other languages
English (en)
Inventor
Gary Luehr
Shabbir T Anik
Ge Peng
Irina DOTSENKO
Pasit Phiasivongsa
Dante ROMANINI
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59062074&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2018003352(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2018003352A1 publication Critical patent/CL2018003352A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33396—Polymers modified by chemical after-treatment with organic compounds containing nitrogen having oxygen in addition to nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2230/00—Compositions for preparing biodegradable polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Polymers & Plastics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polyethers (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Detergent Compositions (AREA)

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA COMPUESTOS CARFILZOMIB PEGILADOS POLIMÉRICOS, Y SALES FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS DE LA FÓRMULA I, DONDE R1, R2, CONECTOR, PEG, N Y O SON TAL COMO SE DEFINEN EN LA PRESENTE MEMORIA. LA INVENCIÓN ASIMISMO DA A CONOCER MÉTODOS PARA PREPARAR Y UTILIZAR DICHOS COMPUESTOS PARA TRATAR EL CÁNCER, Y EN PARTICULAR PARA TRATAR LAS MALIGNIDADES HEMATOLÓGICAS, INCLUIDO EL MIELOMA MÚLTIPLE.
CL2018003352A 2016-05-24 2018-11-23 Compuestos de carfilzomib pegilados. CL2018003352A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662340926P 2016-05-24 2016-05-24
US201762485812P 2017-04-14 2017-04-14

Publications (1)

Publication Number Publication Date
CL2018003352A1 true CL2018003352A1 (es) 2019-02-15

Family

ID=59062074

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018003352A CL2018003352A1 (es) 2016-05-24 2018-11-23 Compuestos de carfilzomib pegilados.

Country Status (26)

Country Link
US (3) US10517954B2 (es)
EP (1) EP3464277B1 (es)
JP (1) JP7142578B2 (es)
KR (1) KR102492135B1 (es)
CN (1) CN109415353B (es)
AU (1) AU2017272101B2 (es)
CA (1) CA3025170A1 (es)
CL (1) CL2018003352A1 (es)
CO (1) CO2018013112A2 (es)
CR (1) CR20180602A (es)
ES (1) ES2939849T3 (es)
IL (1) IL263147B (es)
MA (1) MA45148A (es)
MX (1) MX386616B (es)
MY (1) MY203143A (es)
NZ (1) NZ748615A (es)
PE (1) PE20190328A1 (es)
PH (1) PH12018502473B1 (es)
SA (1) SA518400493B1 (es)
SG (2) SG10201912278TA (es)
TN (1) TN2018000393A1 (es)
TW (1) TWI759301B (es)
UA (1) UA125254C2 (es)
UY (1) UY37253A (es)
WO (1) WO2017205392A1 (es)
ZA (1) ZA201807890B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230161532A (ko) 2015-11-24 2023-11-27 메사추세츠 인스티튜트 오브 테크놀로지 치매를 예방, 경감 및/또는 치료하기 위한 시스템 및 방법
TWI759301B (zh) 2016-05-24 2022-04-01 美商安美基公司 聚乙二醇化卡非佐米化合物
WO2018094230A2 (en) 2016-11-17 2018-05-24 Cognito Therapeutics, Inc. Methods and systems for neural stimulation via auditory stimulation
CA3068318A1 (en) 2017-06-30 2019-01-03 Massachusetts Institute Of Technology Branched multi-functional macromonomers and related polymers and uses thereof
EP3694464B1 (en) 2017-10-10 2025-12-10 Massachusetts Institute of Technology Systems for preventing, mitigating, and/or treating dementia
CN120884714A (zh) * 2017-11-16 2025-11-04 美国安进公司 聚乙二醇化卡非佐米化合物的稳定的组合物
WO2019200367A1 (en) * 2018-04-13 2019-10-17 Massachusetts Institute Of Technology Brush prodrugs and uses thereof
AU2020296295B2 (en) * 2019-06-21 2025-05-29 Ascendis Pharma A/S Conjugates of an electron-donating nitrogen or tertiary amine comprising compounds
KR20220085791A (ko) 2019-10-16 2022-06-22 메사추세츠 인스티튜트 오브 테크놀로지 브러시 전구약물 및 그의 용도
CN115279339A (zh) * 2020-01-10 2022-11-01 美国安进公司 稳定的无环糊精的卡非佐米配制品
WO2021222783A1 (en) * 2020-05-01 2021-11-04 Angiex, Inc. Anti-tm4sf1 antibody drug conjugates and methods of using same
IL298857A (en) * 2020-06-19 2023-02-01 Amgen Inc Methods of measuring carfilzomib
CN113979895B (zh) * 2020-07-08 2023-03-24 中国科学技术大学 一种精确序列可控的自降解聚合物及其制备方法和应用
CN115873231B (zh) * 2022-12-17 2024-10-25 华南理工大学 一种聚乙二醇修饰的氨基糖苷类分子及其制备方法和应用
WO2025035020A2 (en) 2023-08-09 2025-02-13 Amgen Inc. Methods of using carfilzomib
KR20250153899A (ko) 2024-04-18 2025-10-28 충남대학교산학협력단 카르필조밉을 포함하는 자가 나노유화 약물전달시스템 조성물 및 이의 제조방법

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
ES2199935T3 (es) 1991-03-15 2004-03-01 Amgen Inc. Pegilacion de polipeptidos.
US20040100225A1 (en) 2002-11-20 2004-05-27 Neil Robert Miles Cooling and control system for battery charging
WO2005063777A1 (en) 2003-12-23 2005-07-14 Corus Pharma Benzylphosphate and substituted benzylphosphate prodrugs for the treatment of pulmonary inflammation
US7232818B2 (en) * 2004-04-15 2007-06-19 Proteolix, Inc. Compounds for enzyme inhibition
US20050256324A1 (en) 2004-05-10 2005-11-17 Proteolix, Inc. Synthesis of amino acid keto-epoxides
ES2408216T3 (es) * 2004-12-07 2013-06-19 Onyx Therapeutics, Inc. Composición para la inhibición del proteasoma
JP5073315B2 (ja) 2006-03-24 2012-11-14 関西ペイント株式会社 缶用塗料組成物
MX2010003732A (es) 2007-10-04 2010-08-09 Onyx Therapeutics Inc Inhibidores de peptido cetona epoxi de proteasa cristalina y la sintesis de ceto-epoxidos de aminoacido.
WO2009152160A1 (en) 2008-06-10 2009-12-17 Gilead Sciences, Inc. Inhaled carbaprostacyclin and prostacyclin prodrugs for the treatment of pulmonary arterial hypertension
MX2011003117A (es) 2008-09-19 2011-04-21 Nektar Therapeutics Conjugados polimericos de peptidos terapeuticos.
PE20120059A1 (es) 2008-10-21 2012-02-27 Onyx Therapeutics Inc Combinaciones farmaceuticas con epoxicetonas peptidicas
EP2521711B1 (en) 2010-01-07 2017-08-16 Alkermes Pharma Ireland Limited Quaternary ammonium salt prodrugs
BR112012028726B1 (pt) * 2012-05-08 2021-07-13 Onyx Therapeutics, Inc. Método para preparar uma composição farmacêutica com baixo teor de cloreto
US9309283B2 (en) 2012-07-09 2016-04-12 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
US10022326B2 (en) 2012-07-18 2018-07-17 Onyx Therapeutics, Inc. Liposomal compositions of epoxyketone-based proteasome inhibitors
DE102013104003B3 (de) 2013-04-19 2014-03-13 Glatt Systemtechnik Gmbh Vorrichtung zum Einbringen einer definierten Menge eines zweiten Pulvers in einen Prozessbehälter
WO2016004221A1 (en) 2014-07-01 2016-01-07 Mayo Foundation For Medical Education And Research Methods and materials for identifying and treating mammals resistant to proteasome inhibitor treatments
CN104530413B (zh) * 2014-10-01 2017-08-25 厦门赛诺邦格生物科技股份有限公司 一种多官能化h型聚乙二醇衍生物修饰的生物相关物质
CN106310289B (zh) 2015-06-24 2020-10-13 天津键凯科技有限公司 一种聚乙二醇和麻醉药的结合物及其制备方法
EA201891620A1 (ru) 2016-02-05 2019-02-28 Денали Терапьютикс Инк. Ингибиторы взаимодействующей с рецептором протеинкиназы 1
ES2643856B1 (es) 2016-05-24 2018-08-03 Universidad Del Pais Vasco / Euskal Herriko Unibertsitatea Triazoles para la regulación de la homeostasis de calcio intracelular
PE20190117A1 (es) 2016-05-24 2019-01-16 Novo Nordisk As Compuestos de mic-1 y usos de estos
AU2017269746B2 (en) 2016-05-24 2021-09-30 Basf Se Herbicidal uracilpyrid
TWI759301B (zh) 2016-05-24 2022-04-01 美商安美基公司 聚乙二醇化卡非佐米化合物
TN2018000392A1 (en) 2016-05-25 2020-06-15 Bayer Pharma AG 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides
MA45493A (fr) 2016-06-27 2019-05-01 Aicuris Anti Infective Cures Gmbh Inhibiteurs d'entrée de hcmv.
JP6631420B2 (ja) 2016-06-28 2020-01-15 株式会社デンソー 光センサ
JP6851640B2 (ja) 2016-06-30 2021-03-31 Ｆｓテクニカル株式会社 供試体、アンカー試験装置およびアンカー試験方法
CN108603321A (zh) 2016-06-30 2018-09-28 松下知识产权经营株式会社 洗涤装置的操作方法及其程序
JP6512183B2 (ja) 2016-06-30 2019-05-15 株式会社Ｓｏｋｅｎ 乗員検知システム及び乗員検知装置

Also Published As

Publication number Publication date
US11077198B2 (en) 2021-08-03
PH12018502473A1 (en) 2019-04-08
SA518400493B1 (ar) 2024-01-18
PE20190328A1 (es) 2019-03-05
US10517954B2 (en) 2019-12-31
KR20190010648A (ko) 2019-01-30
WO2017205392A1 (en) 2017-11-30
SG10201912278TA (en) 2020-02-27
NZ748615A (en) 2022-11-25
UA125254C2 (uk) 2022-02-09
ZA201807890B (en) 2019-08-28
TWI759301B (zh) 2022-04-01
PH12018502473B1 (en) 2023-03-22
IL263147A (en) 2018-12-31
CA3025170A1 (en) 2017-11-30
MA45148A (fr) 2019-04-10
MX2018014498A (es) 2019-04-01
MY203143A (en) 2024-06-11
JP2019519530A (ja) 2019-07-11
US20200376131A1 (en) 2020-12-03
BR112018074078A2 (pt) 2019-06-04
JP7142578B2 (ja) 2022-09-27
TW201808345A (zh) 2018-03-16
CR20180602A (es) 2019-03-04
SG11201810396QA (en) 2018-12-28
EP3464277A1 (en) 2019-04-10
AU2017272101B2 (en) 2021-10-07
CO2018013112A2 (es) 2018-12-28
ES2939849T3 (es) 2023-04-27
EP3464277B1 (en) 2022-12-28
AU2017272101A1 (en) 2018-12-13
IL263147B (en) 2022-04-01
KR102492135B1 (ko) 2023-01-26
MX386616B (es) 2025-03-19
US20170340746A1 (en) 2017-11-30
US20200069808A1 (en) 2020-03-05
CN109415353B (zh) 2023-01-10
TN2018000393A1 (en) 2020-06-15
CN109415353A (zh) 2019-03-01
UY37253A (es) 2017-11-30
US10675353B2 (en) 2020-06-09

Similar Documents

Publication Publication Date Title
CL2018003352A1 (es) Compuestos de carfilzomib pegilados.
CY1124592T1 (el) Ζιζανιοκτονως δραστικα 3-φαινυλοïσοξαζολινο-5-καρβοξαμιδια αποτελουμενα απο τετραϋδρο- και διυδροφουρανοκαρβοξυλικα οξεα και εστερες
ECSP17026210A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
CL2018001230A1 (es) Tratamiento de osteoartritis
ECSP18083519A (es) Inhibidores de bromodominios
MX2018002520A (es) Compuesto novedoso de pirazolo[3,4-d] pirimidina o sal del mismo.
CU20170089A7 (es) Derivados de quinazolina utilizados para tratar el vih
CR20170116A (es) Compuestos que inhiben la proteina mcl-1
CL2016003350A1 (es) Inhibidores de demetilasa-1 especifica de lisina
CR20150589A (es) Compuestos de biheteroarilo y usos de los mismos
UY35237A (es) Composiciones que comprenden un compuesto de triazol
UY35238A (es) Composiciones que comprenden un compuesto de triazol
CO2017005038A2 (es) Composicones y métodos de tratamiento con profármacos de tizoxanida, un análogo o sal de la misma
CY1123216T1 (el) Αναστολεις της gls1 για την αντιμετωπιση νοσων
EA201891440A1 (ru) Составы/композиции, содержащие ингибитор btk
CR20150148A (es) Azaindolinas
ECSP16083017A (es) Derivados de diheterociclo enlazado a cicloalquilo
MX391824B (es) Introgresion de un rendimieno qtl en plantas de cucumis sativus.
AR108571A1 (es) Compuestos conjugados de peg y carfilzomib
MX372764B (es) Composición oclusiva para el cuidado personal.